Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Callitas Health Engages Dr. Laura Berman, World-renowned Sex Educator, Researcher & Therapist As Chief Health Advisor

Callitas Health Inc.
Posted on: 08 Jan 18
Callitas Health Engages Dr. Laura Berman, World-renowned Sex Educator, Researcher & Therapist As Chief Health Advisor

PR Newswire

CINCINNATI, Jan. 8, 2018

CINCINNATI, Jan. 8, 2018 /PRNewswire/ --  Callitas Health Inc. (CSE: LILY, OTCBB: MPHMF, FWB: T3F2), (the "Company" or "Callitas") a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that Dr. Laura Berman has joined the Callitas team. She will fill the role of Chief Health Advisor, promoting ToConceive and providing insight and consultation on the development of the Company's other products, both OTC and the prescription drug under development for female sexual dysfunction, Extrinsa.

Dr. Berman is a world-renowned sex and relationship educator, researcher and therapist, as well as TV, radio and internet host, presenting the weeknight radio program "Uncovered with Dr. Laura Berman." She's a New York Times best-selling author on sexual health and pleasure. Dr. Berman also acts as assistant clinical professor of OBGYN and psychiatry at the Feinberg School of Medicine at Northwestern University in Chicago.

The addition of Dr. Berman to the Callitas team emphasizes the Company's commitment to female health and wellness and the importance of ToConceive, Extrinsa, and future sexual health and wellness products to the women's health sphere. "Dr. Berman is one of the most recognized and respected experts and a pioneer in women's sexual health," said Kim Whittemore, women's health advocate and Callitas board member. "She brings unparalleled reach and credibility to the Callitas products."

About Callitas Health

Formed in early 2015, Callitas Health Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J's LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive.

Callitas Health Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol "LILY" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice:  We seek safe harbor

View original content with multimedia:

SOURCE Callitas Health Inc.

PR Newswire

Last updated on: 08/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.